View Future GrowthBioRem 過去の業績過去 基準チェック /56BioRemは、平均年間28.9%の収益成長を遂げていますが、 Commercial Services業界の収益は、年間 成長しています。収益は、平均年間12.2% 13.9%収益成長率で 成長しています。 BioRemの自己資本利益率は32.6%であり、純利益率は11.2%です。主要情報28.91%収益成長率38.70%EPS成長率Commercial Services 業界の成長7.30%収益成長率13.95%株主資本利益率32.56%ネット・マージン11.21%前回の決算情報31 Mar 2026最近の業績更新分析記事 • Apr 29BioRem's (CVE:BRM) Performance Is Even Better Than Its Earnings SuggestBioRem Inc.'s ( CVE:BRM ) strong earnings report was rewarded with a positive stock price move. Our analysis found some...Reported Earnings • Apr 21Full year 2025 earnings released: EPS: CA$0.30 (vs CA$0.19 in FY 2024)Full year 2025 results: EPS: CA$0.30 (up from CA$0.19 in FY 2024). Revenue: CA$42.4m (up 13% from FY 2024). Net income: CA$4.82m (up 58% from FY 2024). Profit margin: 11% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: CA$0.072 (vs CA$0.14 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.072 (down from CA$0.14 in 3Q 2024). Revenue: CA$11.3m (down 24% from 3Q 2024). Net income: CA$1.16m (down 47% from 3Q 2024). Profit margin: 10% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 1.5% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 01BioRem's (CVE:BRM) Soft Earnings Don't Show The Whole PictureSoft earnings didn't appear to concern BioRem Inc.'s ( CVE:BRM ) shareholders over the last week. We did some digging...Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CA$0.046 (vs CA$0.022 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.046 (up from CA$0.022 in 2Q 2024). Revenue: CA$9.43m (up 29% from 2Q 2024). Net income: CA$744.8k (up 119% from 2Q 2024). Profit margin: 7.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, while revenues in the Commercial Services industry in Canada are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 38% per year and the company’s share price has also increased by 38% per year.Reported Earnings • May 29First quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.022 in 1Q 2024)First quarter 2025 results: EPS: CA$0.002 (down from CA$0.022 in 1Q 2024). Revenue: CA$4.73m (down 20% from 1Q 2024). Net income: CA$37.2k (down 89% from 1Q 2024). Profit margin: 0.8% (down from 5.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 2.2% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.すべての更新を表示Recent updates分析記事 • Apr 29BioRem's (CVE:BRM) Performance Is Even Better Than Its Earnings SuggestBioRem Inc.'s ( CVE:BRM ) strong earnings report was rewarded with a positive stock price move. Our analysis found some...Reported Earnings • Apr 21Full year 2025 earnings released: EPS: CA$0.30 (vs CA$0.19 in FY 2024)Full year 2025 results: EPS: CA$0.30 (up from CA$0.19 in FY 2024). Revenue: CA$42.4m (up 13% from FY 2024). Net income: CA$4.82m (up 58% from FY 2024). Profit margin: 11% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CA$2.97, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 33x in the Commercial Services industry in Canada. Total returns to shareholders of 178% over the past three years.お知らせ • Apr 14BioRem Inc., Annual General Meeting, Jun 03, 2026BioRem Inc., Annual General Meeting, Jun 03, 2026.分析記事 • Feb 03Shareholders Would Enjoy A Repeat Of BioRem's (CVE:BRM) Recent Growth In ReturnsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CA$2.79, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Commercial Services industry in Canada. Total returns to shareholders of 166% over the past three years.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$2.76, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Commercial Services industry in Canada. Total returns to shareholders of 229% over the past three years.Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: CA$0.072 (vs CA$0.14 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.072 (down from CA$0.14 in 3Q 2024). Revenue: CA$11.3m (down 24% from 3Q 2024). Net income: CA$1.16m (down 47% from 3Q 2024). Profit margin: 10% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 1.5% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Sep 01BioRem's (CVE:BRM) Soft Earnings Don't Show The Whole PictureSoft earnings didn't appear to concern BioRem Inc.'s ( CVE:BRM ) shareholders over the last week. We did some digging...Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CA$0.046 (vs CA$0.022 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.046 (up from CA$0.022 in 2Q 2024). Revenue: CA$9.43m (up 29% from 2Q 2024). Net income: CA$744.8k (up 119% from 2Q 2024). Profit margin: 7.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, while revenues in the Commercial Services industry in Canada are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 38% per year and the company’s share price has also increased by 38% per year.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$2.33, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Commercial Services industry in Canada. Total returns to shareholders of 174% over the past three years.分析記事 • May 30Market Cool On BioRem Inc.'s (CVE:BRM) EarningsBioRem Inc.'s ( CVE:BRM ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now compared...Reported Earnings • May 29First quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.022 in 1Q 2024)First quarter 2025 results: EPS: CA$0.002 (down from CA$0.022 in 1Q 2024). Revenue: CA$4.73m (down 20% from 1Q 2024). Net income: CA$37.2k (down 89% from 1Q 2024). Profit margin: 0.8% (down from 5.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 2.2% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$2.18, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Commercial Services industry in Canada. Total returns to shareholders of 207% over the past three years.Reported Earnings • Apr 16Full year 2024 earnings released: EPS: CA$0.19 (vs CA$0.14 in FY 2023)Full year 2024 results: EPS: CA$0.19 (up from CA$0.14 in FY 2023). Revenue: CA$37.4m (up 49% from FY 2023). Net income: CA$3.04m (up 40% from FY 2023). Profit margin: 8.1% (down from 8.7% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 09BioRem Inc., Annual General Meeting, Jun 03, 2025BioRem Inc., Annual General Meeting, Jun 03, 2025.分析記事 • Feb 13Is BioRem (CVE:BRM) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Recent Insider Transactions • Dec 05CEO, President & Director recently sold CA$352k worth of stockOn the 2nd of December, Derek Webb sold around 120k shares on-market at roughly CA$2.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Derek's only on-market trade for the last 12 months.New Risk • Nov 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (CA$48.5m market cap, or US$34.6m).Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 27%After last week's 27% share price gain to CA$3.13, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 27x in the Commercial Services industry in Canada. Total returns to shareholders of 260% over the past three years.Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: CA$0.14 (vs CA$0.032 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.14 (up from CA$0.032 in 3Q 2023). Revenue: CA$14.9m (up 170% from 3Q 2023). Net income: CA$2.19m (up 336% from 3Q 2023). Profit margin: 15% (up from 9.1% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.分析記事 • Oct 11Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)With a price-to-earnings (or "P/E") ratio of 11.6x BioRem Inc. ( CVE:BRM ) may be sending bullish signals at the...Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CA$0.021 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.021 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$7.30m (up 71% from 2Q 2023). Net income: CA$339.8k (up CA$436.3k from 2Q 2023). Profit margin: 4.7% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year whereas the company’s share price has increased by 55% per year.Reported Earnings • May 29First quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.036 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0.022 (up from CA$0.036 loss in 1Q 2023). Revenue: CA$5.92m (up 87% from 1Q 2023). Net income: CA$344.1k (up CA$901.6k from 1Q 2023). Profit margin: 5.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Apr 19Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)The market for BioRem Inc.'s ( CVE:BRM ) stock was strong after it released a healthy earnings report last week...お知らせ • Apr 13BioRem Inc., Annual General Meeting, Jun 04, 2024BioRem Inc., Annual General Meeting, Jun 04, 2024.分析記事 • Apr 12BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs RewardBioRem Inc. ( CVE:BRM ) shares have continued their recent momentum with a 35% gain in the last month alone. Looking...Reported Earnings • Apr 11Full year 2023 earnings released: EPS: CA$0.14 (vs CA$0.10 in FY 2022)Full year 2023 results: EPS: CA$0.14 (up from CA$0.10 in FY 2022). Revenue: CA$25.2m (down 13% from FY 2022). Net income: CA$2.18m (up 35% from FY 2022). Profit margin: 8.7% (up from 5.6% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • Jan 25BioRem (CVE:BRM) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improves as stock rises 39%After last week's 39% share price gain to CA$1.40, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 24x in the Commercial Services industry in Canada. Total returns to shareholders of 119% over the past three years.Reported Earnings • Dec 01Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.049 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (down from CA$0.049 in 3Q 2022). Revenue: CA$5.51m (down 25% from 3Q 2022). Net income: CA$503.1k (down 34% from 3Q 2022). Profit margin: 9.1% (down from 10% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.Board Change • Sep 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Aug 26Is BioRem (CVE:BRM) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 17% per year over the past 5 years. High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (CA$16.3m market cap, or US$12.0m).Reported Earnings • Aug 24Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.011 profit in 2Q 2022)Second quarter 2023 results: CA$0.006 loss per share (down from CA$0.011 profit in 2Q 2022). Revenue: CA$4.28m (down 32% from 2Q 2022). Net loss: CA$96.5k (down 159% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.01, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 25x in the Commercial Services industry in Canada. Total returns to shareholders of 221% over the past three years.Reported Earnings • May 26First quarter 2023 earnings released: CA$0.036 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.036 loss per share (further deteriorated from CA$0.007 loss in 1Q 2022). Revenue: CA$3.17m (down 28% from 1Q 2022). Net loss: CA$557.5k (loss widened 452% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 06Full year 2022 earnings released: EPS: CA$0.10 (vs CA$0.036 in FY 2021)Full year 2022 results: EPS: CA$0.10 (up from CA$0.036 in FY 2021). Revenue: CA$28.9m (up 18% from FY 2021). Net income: CA$1.61m (up 24% from FY 2021). Profit margin: 5.6% (up from 5.3% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 23Here's Why BioRem (CVE:BRM) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.05 (up from CA$0.003 loss in 3Q 2021). Revenue: CA$7.31m (up 60% from 3Q 2021). Net income: CA$761.2k (up CA$876.6k from 3Q 2021). Profit margin: 10% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 40% per year.分析記事 • Aug 25BioRem (CVE:BRM) Could Easily Take On More DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.007 in 2Q 2021)Second quarter 2022 results: EPS: CA$0.011. Revenue: CA$6.26m (up 11% from 2Q 2021). Net income: CA$164.3k (down 38% from 2Q 2021). Profit margin: 2.6% (down from 4.7% in 2Q 2021). The decrease in margin was driven by higher expenses.Reported Earnings • May 26First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 1Q 2021)First quarter 2022 results: CA$0.007 loss per share (up from CA$0.011 loss in 1Q 2021). Revenue: CA$4.38m (up 28% from 1Q 2021). Net loss: CA$101.0k (loss narrowed 76% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.分析記事 • May 20These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...お知らせ • Apr 09BIOREM Inc., Annual General Meeting, Jun 14, 2022BIOREM Inc., Annual General Meeting, Jun 14, 2022.Reported Earnings • Mar 30Full year 2021 earnings released: EPS: CA$0.036 (vs CA$0.054 in FY 2020)Full year 2021 results: EPS: CA$0.036 (down from CA$0.054 in FY 2020). Revenue: CA$24.5m (flat on FY 2020). Net income: CA$1.30m (down 38% from FY 2020). Profit margin: 5.3% (down from 8.6% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.分析記事 • Jan 26Here's What's Concerning About BIOREM's (CVE:BRM) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...Reported Earnings • Nov 26Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CA$4.58m (up 28% from 3Q 2020). Net loss: CA$115.4k (down 174% from profit in 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.お知らせ • Aug 06BIOREM Inc. (TSXV:BRM) announces an Equity Buyback for 23,434,121 shares, for CAD 12.32 million.BIOREM Inc. (TSXV:BRM) announces a share repurchase program. Under the program, the company will repurchase up to 23,434,121 shares at a price of $0.5256 per share, for CAD 12.32 million. The program is expected to be financed through the use of a portion of the company's existing cash reserves and the proceeds from the issuance of $5 million in term debt. The program is subject to regulatory and disinterested shareholder approval at a special meeting to be held on September 16, 2021.Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jul 29Second quarter 2021 earnings released: EPS CA$0.007 (vs CA$0.009 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$5.63m (down 5.4% from 2Q 2020). Net income: CA$266.4k (down 21% from 2Q 2020). Profit margin: 4.7% (down from 5.7% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Board Change • Jul 29High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 21First quarter 2021 earnings released: EPS CA$0.01 (vs CA$0.01 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: CA$3.43m (down 50% from 1Q 2020). Net loss: CA$420.7k (down 191% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Reported Earnings • Apr 02Full year 2020 earnings released: EPS CA$0.05 (vs CA$0.034 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$24.4m (up 18% from FY 2019). Net income: CA$2.09m (up CA$3.39m from FY 2019). Profit margin: 8.6% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.お知らせ • Jan 28BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite IndexBIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite IndexIs New 90 Day High Low • Jan 06New 90-day high: CA$0.64The company is up 80% from its price of CA$0.35 on 06 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 16% over the same period.お知らせ • Dec 15BIOREM Inc. Announces Research Project with City of New York to Control Release of Bioaerosols from Waste Water Treatment FacilitiesBIOREM Inc. announced a research project in collaboration with the City of New York to examine the efficacy of BIOREM's enhanced biological processes for the mitigation of odours and hazardous air pollutants from various wastewater treatment facilities under their operation. A key component of the research and demonstration project will be to look at the effectiveness of BIOREM's systems to reduce or eliminate the transmission of bioaerosols from these emissions. BIOREM has designed a dual-stage biological system specifically optimized to address the types of emissions anticipated from the various processes. The unit has been constructed and delivered to the first study location. The overall length of the research project is expected to last for one year.Is New 90 Day High Low • Dec 15New 90-day high: CA$0.58The company is up 71% from its price of CA$0.34 on 14 September 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 19% over the same period.お知らせ • Dec 10BIOREM Inc. Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC EmissionsBIOREM Inc. announced the successful completion of two research projects for the mitigation of volatile organic compounds from complex industrial gas emissions. Both projects were to assess and compare the efficacy of BIOREM's enhanced biological processes against legacy abatement technologies. Historically, thermal oxidation or chemical scrubbing has been utilized for mitigating complex industrial emissions. The high operating costs, safety concerns and generation of secondary contaminants all contribute to very large carbon footprints for these technologies.分析記事 • Nov 23Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay ChequeThis article will reflect on the compensation paid to Derek Webb who has served as CEO of BIOREM Inc. (CVE:BRM) since...収支内訳BioRem の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史TSXV:BRM 収益、費用、利益 ( )CAD Millions日付収益収益G+A経費研究開発費31 Mar 264456031 Dec 254256030 Sep 253525030 Jun 253836031 Mar 253635031 Dec 243736030 Sep 244056030 Jun 243144031 Mar 242834031 Dec 232524030 Sep 232415030 Jun 232616031 Mar 232816031 Dec 222926030 Sep 222925030 Jun 222624031 Mar 222524031 Dec 212414030 Sep 212215030 Jun 212114031 Mar 212115031 Dec 202425030 Sep 2021-15030 Jun 2023-16031 Mar 2023-16031 Dec 1921-16030 Sep 192756030 Jun 192555031 Mar 192555031 Dec 182455030 Sep 182214030 Jun 182324031 Mar 182314031 Dec 172324030 Sep 171914030 Jun 171804031 Mar 171504031 Dec 161613030 Sep 161413030 Jun 161513031 Mar 161624031 Dec 151724030 Sep 151824030 Jun 1516141質の高い収益: BRM 非現金収入 のレベルが高いです。利益率の向上: BRMの現在の純利益率 (11.2%)は、昨年(7.6%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BRMの収益は過去 5 年間で年間28.9%増加しました。成長の加速: BRMの過去 1 年間の収益成長率 ( 82% ) は、5 年間の平均 ( 年間28.9%を上回っています。収益対業界: BRMの過去 1 年間の収益成長率 ( 82% ) はCommercial Services業界9.8%を上回りました。株主資本利益率高いROE: BRMの 自己資本利益率 ( 32.6% ) は 高い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YCommercial-services 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 21:12終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BioRem Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Nicholas BoychukATB CormarkNicholas BoychukATB Cormark Historical (Cormark Securities)
分析記事 • Apr 29BioRem's (CVE:BRM) Performance Is Even Better Than Its Earnings SuggestBioRem Inc.'s ( CVE:BRM ) strong earnings report was rewarded with a positive stock price move. Our analysis found some...
Reported Earnings • Apr 21Full year 2025 earnings released: EPS: CA$0.30 (vs CA$0.19 in FY 2024)Full year 2025 results: EPS: CA$0.30 (up from CA$0.19 in FY 2024). Revenue: CA$42.4m (up 13% from FY 2024). Net income: CA$4.82m (up 58% from FY 2024). Profit margin: 11% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: CA$0.072 (vs CA$0.14 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.072 (down from CA$0.14 in 3Q 2024). Revenue: CA$11.3m (down 24% from 3Q 2024). Net income: CA$1.16m (down 47% from 3Q 2024). Profit margin: 10% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 1.5% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 01BioRem's (CVE:BRM) Soft Earnings Don't Show The Whole PictureSoft earnings didn't appear to concern BioRem Inc.'s ( CVE:BRM ) shareholders over the last week. We did some digging...
Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CA$0.046 (vs CA$0.022 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.046 (up from CA$0.022 in 2Q 2024). Revenue: CA$9.43m (up 29% from 2Q 2024). Net income: CA$744.8k (up 119% from 2Q 2024). Profit margin: 7.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, while revenues in the Commercial Services industry in Canada are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 38% per year and the company’s share price has also increased by 38% per year.
Reported Earnings • May 29First quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.022 in 1Q 2024)First quarter 2025 results: EPS: CA$0.002 (down from CA$0.022 in 1Q 2024). Revenue: CA$4.73m (down 20% from 1Q 2024). Net income: CA$37.2k (down 89% from 1Q 2024). Profit margin: 0.8% (down from 5.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 2.2% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 29BioRem's (CVE:BRM) Performance Is Even Better Than Its Earnings SuggestBioRem Inc.'s ( CVE:BRM ) strong earnings report was rewarded with a positive stock price move. Our analysis found some...
Reported Earnings • Apr 21Full year 2025 earnings released: EPS: CA$0.30 (vs CA$0.19 in FY 2024)Full year 2025 results: EPS: CA$0.30 (up from CA$0.19 in FY 2024). Revenue: CA$42.4m (up 13% from FY 2024). Net income: CA$4.82m (up 58% from FY 2024). Profit margin: 11% (up from 8.1% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 19%After last week's 19% share price gain to CA$2.97, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 33x in the Commercial Services industry in Canada. Total returns to shareholders of 178% over the past three years.
お知らせ • Apr 14BioRem Inc., Annual General Meeting, Jun 03, 2026BioRem Inc., Annual General Meeting, Jun 03, 2026.
分析記事 • Feb 03Shareholders Would Enjoy A Repeat Of BioRem's (CVE:BRM) Recent Growth In ReturnsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? One common...
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 18%After last week's 18% share price gain to CA$2.79, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Commercial Services industry in Canada. Total returns to shareholders of 166% over the past three years.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$2.76, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 18x in the Commercial Services industry in Canada. Total returns to shareholders of 229% over the past three years.
Reported Earnings • Nov 19Third quarter 2025 earnings released: EPS: CA$0.072 (vs CA$0.14 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.072 (down from CA$0.14 in 3Q 2024). Revenue: CA$11.3m (down 24% from 3Q 2024). Net income: CA$1.16m (down 47% from 3Q 2024). Profit margin: 10% (down from 15% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 1.5% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Sep 01BioRem's (CVE:BRM) Soft Earnings Don't Show The Whole PictureSoft earnings didn't appear to concern BioRem Inc.'s ( CVE:BRM ) shareholders over the last week. We did some digging...
Reported Earnings • Aug 26Second quarter 2025 earnings released: EPS: CA$0.046 (vs CA$0.022 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.046 (up from CA$0.022 in 2Q 2024). Revenue: CA$9.43m (up 29% from 2Q 2024). Net income: CA$744.8k (up 119% from 2Q 2024). Profit margin: 7.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.2% p.a. on average during the next 2 years, while revenues in the Commercial Services industry in Canada are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 38% per year and the company’s share price has also increased by 38% per year.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$2.33, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Commercial Services industry in Canada. Total returns to shareholders of 174% over the past three years.
分析記事 • May 30Market Cool On BioRem Inc.'s (CVE:BRM) EarningsBioRem Inc.'s ( CVE:BRM ) price-to-earnings (or "P/E") ratio of 10.7x might make it look like a buy right now compared...
Reported Earnings • May 29First quarter 2025 earnings released: EPS: CA$0.002 (vs CA$0.022 in 1Q 2024)First quarter 2025 results: EPS: CA$0.002 (down from CA$0.022 in 1Q 2024). Revenue: CA$4.73m (down 20% from 1Q 2024). Net income: CA$37.2k (down 89% from 1Q 2024). Profit margin: 0.8% (down from 5.8% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 2.2% decline forecast for the Commercial Services industry in Canada. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • May 14Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$2.18, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 11x in the Commercial Services industry in Canada. Total returns to shareholders of 207% over the past three years.
Reported Earnings • Apr 16Full year 2024 earnings released: EPS: CA$0.19 (vs CA$0.14 in FY 2023)Full year 2024 results: EPS: CA$0.19 (up from CA$0.14 in FY 2023). Revenue: CA$37.4m (up 49% from FY 2023). Net income: CA$3.04m (up 40% from FY 2023). Profit margin: 8.1% (down from 8.7% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 09BioRem Inc., Annual General Meeting, Jun 03, 2025BioRem Inc., Annual General Meeting, Jun 03, 2025.
分析記事 • Feb 13Is BioRem (CVE:BRM) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Recent Insider Transactions • Dec 05CEO, President & Director recently sold CA$352k worth of stockOn the 2nd of December, Derek Webb sold around 120k shares on-market at roughly CA$2.93 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Derek's only on-market trade for the last 12 months.
New Risk • Nov 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (CA$48.5m market cap, or US$34.6m).
Valuation Update With 7 Day Price Move • Nov 13Investor sentiment improves as stock rises 27%After last week's 27% share price gain to CA$3.13, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 27x in the Commercial Services industry in Canada. Total returns to shareholders of 260% over the past three years.
Reported Earnings • Nov 07Third quarter 2024 earnings released: EPS: CA$0.14 (vs CA$0.032 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.14 (up from CA$0.032 in 3Q 2023). Revenue: CA$14.9m (up 170% from 3Q 2023). Net income: CA$2.19m (up 336% from 3Q 2023). Profit margin: 15% (up from 9.1% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 45% per year, which means it is significantly lagging earnings growth.
分析記事 • Oct 11Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)With a price-to-earnings (or "P/E") ratio of 11.6x BioRem Inc. ( CVE:BRM ) may be sending bullish signals at the...
Reported Earnings • Aug 27Second quarter 2024 earnings released: EPS: CA$0.021 (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: EPS: CA$0.021 (up from CA$0.006 loss in 2Q 2023). Revenue: CA$7.30m (up 71% from 2Q 2023). Net income: CA$339.8k (up CA$436.3k from 2Q 2023). Profit margin: 4.7% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year whereas the company’s share price has increased by 55% per year.
Reported Earnings • May 29First quarter 2024 earnings released: EPS: CA$0.022 (vs CA$0.036 loss in 1Q 2023)First quarter 2024 results: EPS: CA$0.022 (up from CA$0.036 loss in 1Q 2023). Revenue: CA$5.92m (up 87% from 1Q 2023). Net income: CA$344.1k (up CA$901.6k from 1Q 2023). Profit margin: 5.8% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Apr 19Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)The market for BioRem Inc.'s ( CVE:BRM ) stock was strong after it released a healthy earnings report last week...
お知らせ • Apr 13BioRem Inc., Annual General Meeting, Jun 04, 2024BioRem Inc., Annual General Meeting, Jun 04, 2024.
分析記事 • Apr 12BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs RewardBioRem Inc. ( CVE:BRM ) shares have continued their recent momentum with a 35% gain in the last month alone. Looking...
Reported Earnings • Apr 11Full year 2023 earnings released: EPS: CA$0.14 (vs CA$0.10 in FY 2022)Full year 2023 results: EPS: CA$0.14 (up from CA$0.10 in FY 2022). Revenue: CA$25.2m (down 13% from FY 2022). Net income: CA$2.18m (up 35% from FY 2022). Profit margin: 8.7% (up from 5.6% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • Jan 25BioRem (CVE:BRM) Has A Pretty Healthy Balance SheetLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment improves as stock rises 39%After last week's 39% share price gain to CA$1.40, the stock trades at a trailing P/E ratio of 34.3x. Average trailing P/E is 24x in the Commercial Services industry in Canada. Total returns to shareholders of 119% over the past three years.
Reported Earnings • Dec 01Third quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.049 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.03 (down from CA$0.049 in 3Q 2022). Revenue: CA$5.51m (down 25% from 3Q 2022). Net income: CA$503.1k (down 34% from 3Q 2022). Profit margin: 9.1% (down from 10% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 27% per year, which means it is significantly lagging earnings growth.
Board Change • Sep 12Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Aug 26Is BioRem (CVE:BRM) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Aug 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 17% per year over the past 5 years. High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Profit margins are more than 30% lower than last year (3.5% net profit margin). Market cap is less than US$100m (CA$16.3m market cap, or US$12.0m).
Reported Earnings • Aug 24Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.011 profit in 2Q 2022)Second quarter 2023 results: CA$0.006 loss per share (down from CA$0.011 profit in 2Q 2022). Revenue: CA$4.28m (down 32% from 2Q 2022). Net loss: CA$96.5k (down 159% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 38% per year, which means it is significantly lagging earnings growth.
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. Independent Chairman of the Board Bill White was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.01, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 25x in the Commercial Services industry in Canada. Total returns to shareholders of 221% over the past three years.
Reported Earnings • May 26First quarter 2023 earnings released: CA$0.036 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.036 loss per share (further deteriorated from CA$0.007 loss in 1Q 2022). Revenue: CA$3.17m (down 28% from 1Q 2022). Net loss: CA$557.5k (loss widened 452% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 81% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 06Full year 2022 earnings released: EPS: CA$0.10 (vs CA$0.036 in FY 2021)Full year 2022 results: EPS: CA$0.10 (up from CA$0.036 in FY 2021). Revenue: CA$28.9m (up 18% from FY 2021). Net income: CA$1.61m (up 24% from FY 2021). Profit margin: 5.6% (up from 5.3% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has only increased by 44% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 23Here's Why BioRem (CVE:BRM) Can Manage Its Debt ResponsiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: CA$0.05 (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.05 (up from CA$0.003 loss in 3Q 2021). Revenue: CA$7.31m (up 60% from 3Q 2021). Net income: CA$761.2k (up CA$876.6k from 3Q 2021). Profit margin: 10% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year whereas the company’s share price has increased by 40% per year.
分析記事 • Aug 25BioRem (CVE:BRM) Could Easily Take On More DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.007 in 2Q 2021)Second quarter 2022 results: EPS: CA$0.011. Revenue: CA$6.26m (up 11% from 2Q 2021). Net income: CA$164.3k (down 38% from 2Q 2021). Profit margin: 2.6% (down from 4.7% in 2Q 2021). The decrease in margin was driven by higher expenses.
Reported Earnings • May 26First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.011 loss in 1Q 2021)First quarter 2022 results: CA$0.007 loss per share (up from CA$0.011 loss in 1Q 2021). Revenue: CA$4.38m (up 28% from 1Q 2021). Net loss: CA$101.0k (loss narrowed 76% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
分析記事 • May 20These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably WellSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
お知らせ • Apr 09BIOREM Inc., Annual General Meeting, Jun 14, 2022BIOREM Inc., Annual General Meeting, Jun 14, 2022.
Reported Earnings • Mar 30Full year 2021 earnings released: EPS: CA$0.036 (vs CA$0.054 in FY 2020)Full year 2021 results: EPS: CA$0.036 (down from CA$0.054 in FY 2020). Revenue: CA$24.5m (flat on FY 2020). Net income: CA$1.30m (down 38% from FY 2020). Profit margin: 5.3% (down from 8.6% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
分析記事 • Jan 26Here's What's Concerning About BIOREM's (CVE:BRM) Returns On CapitalIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
Reported Earnings • Nov 26Third quarter 2021 earnings: Revenues in line with analyst expectationsThird quarter 2021 results: Revenue: CA$4.58m (up 28% from 3Q 2020). Net loss: CA$115.4k (down 174% from profit in 3Q 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has increased by 34% per year, which means it is well ahead of earnings.
お知らせ • Aug 06BIOREM Inc. (TSXV:BRM) announces an Equity Buyback for 23,434,121 shares, for CAD 12.32 million.BIOREM Inc. (TSXV:BRM) announces a share repurchase program. Under the program, the company will repurchase up to 23,434,121 shares at a price of $0.5256 per share, for CAD 12.32 million. The program is expected to be financed through the use of a portion of the company's existing cash reserves and the proceeds from the issuance of $5 million in term debt. The program is subject to regulatory and disinterested shareholder approval at a special meeting to be held on September 16, 2021.
Board Change • Aug 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jul 29Second quarter 2021 earnings released: EPS CA$0.007 (vs CA$0.009 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CA$5.63m (down 5.4% from 2Q 2020). Net income: CA$266.4k (down 21% from 2Q 2020). Profit margin: 4.7% (down from 5.7% in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Board Change • Jul 29High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Director Wei Han was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 21First quarter 2021 earnings released: EPS CA$0.01 (vs CA$0.01 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and control over costs. First quarter 2021 results: Revenue: CA$3.43m (down 50% from 1Q 2020). Net loss: CA$420.7k (down 191% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Reported Earnings • Apr 02Full year 2020 earnings released: EPS CA$0.05 (vs CA$0.034 loss in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CA$24.4m (up 18% from FY 2019). Net income: CA$2.09m (up CA$3.39m from FY 2019). Profit margin: 8.6% (up from net loss in FY 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
お知らせ • Jan 28BIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite IndexBIOREM Inc.(TSXV:BRM) dropped from S&P/TSX Venture Composite Index
Is New 90 Day High Low • Jan 06New 90-day high: CA$0.64The company is up 80% from its price of CA$0.35 on 06 October 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 16% over the same period.
お知らせ • Dec 15BIOREM Inc. Announces Research Project with City of New York to Control Release of Bioaerosols from Waste Water Treatment FacilitiesBIOREM Inc. announced a research project in collaboration with the City of New York to examine the efficacy of BIOREM's enhanced biological processes for the mitigation of odours and hazardous air pollutants from various wastewater treatment facilities under their operation. A key component of the research and demonstration project will be to look at the effectiveness of BIOREM's systems to reduce or eliminate the transmission of bioaerosols from these emissions. BIOREM has designed a dual-stage biological system specifically optimized to address the types of emissions anticipated from the various processes. The unit has been constructed and delivered to the first study location. The overall length of the research project is expected to last for one year.
Is New 90 Day High Low • Dec 15New 90-day high: CA$0.58The company is up 71% from its price of CA$0.34 on 14 September 2020. The Canadian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Commercial Services industry, which is up 19% over the same period.
お知らせ • Dec 10BIOREM Inc. Announces Successful Demonstration Projects Assessing Novel Biological Processes for the Mitigation of Industrial VOC EmissionsBIOREM Inc. announced the successful completion of two research projects for the mitigation of volatile organic compounds from complex industrial gas emissions. Both projects were to assess and compare the efficacy of BIOREM's enhanced biological processes against legacy abatement technologies. Historically, thermal oxidation or chemical scrubbing has been utilized for mitigating complex industrial emissions. The high operating costs, safety concerns and generation of secondary contaminants all contribute to very large carbon footprints for these technologies.
分析記事 • Nov 23Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay ChequeThis article will reflect on the compensation paid to Derek Webb who has served as CEO of BIOREM Inc. (CVE:BRM) since...